TABLE OF CONTENTS
1 INTRODUCTION 46
1.1 OBJECTIVES OF THE STUDY 46
1.2 MARKET DEFINITION 46
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET 46
1.4 LIMITATIONS 48
1.5 MARKETS COVERED 48
2 MARKET SEGMENTATION 51
2.1 MARKETS COVERED 51
2.2 GEOGRAPHICAL SCOPE 52
2.3 YEARS CONSIDERED FOR THE STUDY 53
2.4 CURRENCY AND PRICING 53
2.5 DBMR TRIPOD DATA VALIDATION MODEL 54
2.6 MULTIVARIATE MODELLING 57
2.7 PRODUCT TYPE LIFELINE CURVE 57
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 58
2.9 DBMR MARKET POSITION GRID 59
2.10 MARKET TESTING TYPE COVERAGE GRID 61
2.11 VENDOR SHARE ANALYSIS 62
2.12 SECONDARY SOURCES 63
2.13 ASSUMPTIONS 63
3 EXECUTIVE SUMMARY 64
4 PREMIUM INSIGHTS 67
4.1 PESTEL ANALYSIS 68
4.2 PORTERS FIVE FORCES 69
4.3 GROWTH STRATEGIES ADOPTED BY KEY MARKET PLAYERS 70
5 EPIDEMIOLOGY 71
6 REGULATORY FRAMEWORK OF THE MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET 72
6.1 REGULATORY SCENARIO IN THE U.S. 72
6.2 REGULATORY SCENARIO IN AUSTRALIA 73
6.3 REGULATORY SCENARIO IN JAPAN 73
6.4 REGULATORY SCENARIO IN CHINA 73
7 MARKET OVERVIEW 74
7.1 DRIVERS 76
7.1.1 RISING INCIDENCE AND PREVALENCE OF THYROID NODULES AND CANCER 76
7.1.2 RISING THYROID CANCER DIAGNOSTIC TESTS 76
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 77
7.1.4 RISING AWARENESS TOWARDS THYROID CANCER 77
7.2 RESTRAINTS 78
7.2.1 HIGH COST OF DIAGNOSTICS PROCEDURE 78
7.2.2 TISSUE DAMAGE DUE TO HIGH RADIATION EXPOSURE FROM IMAGING TESTS 79
7.3 OPPORTUNITIES 79
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 79
7.3.2 RISING OBESE POPULATION 80
7.4 CHALLENGES 80
7.4.1 STRINGENT REGULATORY FRAMEWORK FOR THE APPROVAL AND COMMERCIALIZATION OF CANCER DIAGNOSTIC PRODUCTS 80
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE 81
8 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 82
8.1 OVERVIEW 83
8.2 INSTRUMENTS 86
8.2.1 PATHOLOGY BASED INSTRUMENTS 87
8.2.1.1 PCR INSTRUMENTS 87
8.2.1.2 SLIDE STAINING SYSTEMS 87
8.2.1.3 TISSUE PROCESSING SYSTEMS 87
8.2.1.4 CELL PROCESSORS 88
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 88
8.2.2 IMAGING INSTRUMENTS 88
8.2.2.1 ULTRASOUND SYSTEMS 88
8.2.2.2 CT SYSTEMS 88
8.2.2.3 MRI SYSTEMS 88
8.2.2.4 OTHERS 88
8.2.3 BIOPSY INSTRUMENTS 89
8.2.3.1 NEEDLE BIOPSY 89
8.2.3.2 ENDOSCOPIC BIOPSY 89
8.2.3.3 CORE BIOPSY 89
8.2.3.4 OTHERS 89
8.2.4 OTHERS 89
8.3 CONSUMABLES & ACCESSORIES 90
8.3.1 KITS 91
8.3.1.1 PCR KITS 91
8.3.1.2 DNA POLYMERASE KITS 91
8.3.1.3 NUCLEIC ACID ISOLATION KITS 91
8.3.1.4 OTHERS 91
8.3.2 REAGENTS 92
8.3.2.1 ASSAYS 92
8.3.2.2 BUFFERS 92
8.3.2.3 PRIMERS 92
8.3.2.4 OTHERS 92
8.3.3 PROBES 92
8.3.4 OTHER CONSUMABLES 92
9 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY TEST TYPE 93
9.1 OVERVIEW 94
9.2 IMAGING TEST 97
9.2.1 COMPUTED TOMOGRAPHY (CT) SCAN 98
9.2.2 MRI 98
9.2.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 98
9.2.4 OTHERS 98
9.3 BLOOD TEST 99
9.3.1 BLOOD CHEMISTRY TESTS 100
9.3.2 COMPLETE BLOOD COUNT (CBC) 100
9.3.3 OTHERS 100
9.4 BIOPSY 100
9.4.1 NEEDLE BIOPSY 101
9.4.2 BRONCHOSCOPY BIOPSY 101
9.4.3 CORE BIOPSY 101
9.4.4 OTHERS 101
9.5 OTHERS 102
10 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 103
10.1 OVERVIEW 104
10.2 PAPILLARY CARCINOMA 107
10.3 FOLLICULAR CARCINOMA 108
10.4 OTHERS 109
11 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY STAGES 110
11.1 OVERVIEW 111
11.2 STAGE I 114
11.3 STAGE II 115
11.4 STAGE III 116
11.5 STAGE IV 117
12 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY AGE GROUP 118
12.1 OVERVIEW 119
12.2 30-65 122
12.3 65 AND ABOVE 123
12.4 21-29 124
12.5 BELOW 21 125
13 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY END USER 126
13.1 OVERVIEW 127
13.2 HOSPITALS 130
13.3 ASSOCIATED LABS 131
13.4 INDEPENDENT DIAGNOSTIC LABORATORIES 131
13.5 DIAGNOSTIC IMAGING CENTERS 132
13.6 CANCER RESEARCH INSTITUTES 133
13.7 OTHERS 134
14 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 135
14.1 OVERVIEW 136
14.2 DIRECT TENDER 139
14.3 RETAIL SALES 140
15 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET, BY REGION 141
15.1 MIDDLE EAST AND AFRICA 142
15.1.1 SAUDI ARABIA 153
15.1.2 U.A.E. 158
15.1.3 SOUTH AFRICA 163
15.1.4 EGYPT 169
15.1.5 ISRAEL 174
15.1.6 REST OF MIDDLE EAST AND AFRICA 179
16 MIDDLE EAST & AFRICA THYROID CANCER DIAGNOSTICS MARKET: COMPANY LANDSCAPE 180
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 180
17 SWOT ANALYSIS 181
18 COMPANY PROFILE 182
18.1 CANON INC. 182
18.1.1 COMPANY SNAPSHOT 182
18.1.2 COMPANY SHARE ANALYSIS 182
18.1.3 PRODUCT PORTFOLIO 183
18.1.4 RECENT DEVELOPMENTS 183
18.2 FUJIFILM CORPORATION 184
18.2.1 COMPANY SNAPSHOT 184
18.2.2 REVENUE ANALYSIS 184
18.2.3 COMPANY SHARE ANALYSIS 185
18.2.4 PRODUCT PORTFOLIO 185
18.2.5 RECENT DEVELOPMENT 185
18.3 F. HOFFMANN-LA ROCHE LTD 186
18.3.1 COMPANY SNAPSHOT 186
18.3.2 REVENUE ANALYSIS 186
18.3.3 COMPANY SHARE ANALYSIS 187
18.3.4 PRODUCT PORTFOLIO 187
18.3.5 RECENT DEVELOPMENT 187
18.4 QUEST DIAGNOSTICS INCORPORATED 188
18.4.1 COMPANY SNAPSHOT 188
18.4.2 REVENUE ANALYSIS 188
18.4.3 COMPANY SHARE ANALYSIS 189
18.4.4 PRODUCT PORTFOLIO 189
18.4.5 RECENT DEVELOPMENTS 189
18.5 ILLUMINA, INC. 191
18.5.1 COMPANY SNAPSHOT 191
18.5.2 REVENUE ANALYSIS 191
18.5.3 COMPANY SHARE ANALYSIS 192
18.5.4 PRODUCT PORTFOLIO 192
18.5.5 RECENT DEVELOPMENT 192
18.6 ABBOTT 193
18.6.1 COMPANY SNAPSHOT 193
18.6.2 REVENUE ANALYSIS 193
18.6.3 PRODUCT PORTFOLIO 194
18.6.4 RECENT DEVELOPMENT 194
18.7 BD 195
18.7.1 COMPANY SNAPSHOT 195
18.7.2 REVENUE ANALYSIS 195
18.7.3 PRODUCT PORTFOLIO 196
18.7.4 RECENT DEVELOPMENT 196
18.8 BEIJING O&D BIOTECH CO., LTD. 197
18.8.1 COMPANY SNAPSHOT 197
18.8.2 PRODUCT PORTFOLIO 197
18.8.3 RECENT DEVELOPMENTS 197
18.9 BIOMRIEUX SA 198
18.9.1 COMPANY SNAPSHOT 198
18.9.2 REVENUE ANALYSIS 198
18.9.3 PRODUCT PORTFOLIO 199
18.9.4 RECENT DEVELOPMENTS 199
18.10 DIASORIN S.P.A. 200
18.10.1 COMPANY SNAPSHOT 200
18.10.2 REVENUE ANALYSIS 200
18.10.3 PRODUCT PORTFOLIO 201
18.10.4 RECENT DEVELOPMENT 201
18.11 FONAR CORP. 202
18.11.1 COMPANY SNAPSHOT 202
18.11.2 REVENUE ANALYSIS 202
18.11.3 PRODUCT PORTFOLIO 203
18.11.4 RECENT DEVELOPMENTS 203
18.12 GENERAL ELECTRIC 204
18.12.1 COMPANY SNAPSHOT 204
18.12.2 REVENUE ANALYSIS 204
18.12.3 PRODUCT PORTFOLIO 205
18.12.4 RECENT DEVELOPMENTS 205
18.13 HOLOGIC INC. 206
18.13.1 COMPANY SNAPSHOT 206
18.13.2 REVENUE ANALYSIS 206
18.13.3 PRODUCT PORTFOLIO 207
18.13.4 RECENT DEVELOPMENT 207
18.14 KONINKLIJKE PHILIPS N.V. 208
18.14.1 COMPANY SNAPSHOT 208
18.14.2 REVENUE ANALYSIS 208
18.14.3 PRODUCT PORTFOLIO 209
18.14.4 RECENT DEVELOPMENT 209
18.15 MERCK KGAA. 210
18.15.1 COMPANY SNAPSHOT 210
18.15.2 REVENUE ANALYSIS 210
18.15.3 PRODUCT PORTFOLIO 211
18.15.4 RECENT DEVELOPMENT 211
18.16 MEDONICA CO. LTD 212
18.16.1 COMPANY SNAPSHOT 212
18.16.2 PRODUCT PORTFOLIO 212
18.16.3 RECENT DEVELOPMENT 212
18.17 MINFOUND MEDICAL SYSTEMS CO. LTD 213
18.17.1 COMPANY SNAPSHOT 213
18.17.2 PRODUCT PORTFOLIO 213
18.17.3 RECENT DEVELOPMENTS 214
18.18 MYRIAD GENETICS, INC. 215
18.18.1 COMPANY SNAPSHOT 215
18.18.2 REVENUE ANALYSIS 215
18.18.3 PRODUCT PORTFOLIO 216
18.18.4 RECENT DEVELOPMENTS 216
18.19 PLEXBIO. 217
18.19.1 COMPANY SNAPSHOT 217
18.19.2 PRODUCT PORTFOLIO 217
18.19.3 RECENT DEVELOPMENTS 217
18.20 QIAGEN 218
18.20.1 COMPANY SNAPSHOT 218
18.20.2 REVENUE ANALYSIS 218
18.20.3 PRODUCT PORTFOLIO 219
18.20.4 RECENT DEVELOPMENT 219
18.21 STERNMED GMBH 220
18.21.1 COMPANY SNAPSHOT 220
18.21.2 PRODUCT PORTFOLIO 220
18.21.3 RECENT DEVELOPMENTS 220

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.